RxPG News Feed for RxPG News

Medical Research Health Special Topics World
 Asian Health
 Food & Nutrition
 Men's Health
 Mental Health
 Occupational Health
 Public Health
 Sleep Hygiene
 Women's Health
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 World Healthcare
   Latest Research
 Alternative Medicine
 Clinical Trials
 Infectious Diseases
  Anorexia Nervosa
  Child Psychiatry
  Forensic Psychiatry
  Mood Disorders
  Peri-Natal Psychiatry
  Personality Disorders
  Sleep Disorders
  Substance Abuse
 Sports Medicine
   Medical News
 Awards & Prizes
   Special Topics
 Odd Medical News

Last Updated: Oct 11, 2012 - 10:22:56 PM
Suicide Channel

subscribe to Suicide newsletter
Latest Research : Psychiatry : Suicide

   EMAIL   |   PRINT
Suicidal behaviour caused by antidepressants 'cannot be ruled out'

Feb 18, 2005 - 5:28:00 PM
"The debate is not yet done, but these papers crystallise arguments that have been drifting in the ether these past months," says Kamran Abbasi, BMJ Acting Editor. "How many people who turned to 'happy pills' would not have done so if they had been fully aware of the potential harms?"

[RxPG] Antidepressant drugs may be associated with an increased risk of suicidal behaviour, particularly in the early stages of treatment, shows new evidence in this week's BMJ.

Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed class of antidepressant, yet concerns have arisen that these drugs may induce or worsen suicidal feelings in vulnerable patients. Three studies published in this issue of BMJ shed new light on the benefits and harms of these drugs.

In the first study, researchers analysed 702 trials involving over 87,000 patients with depression and other clinical conditions to establish whether a link exists between use of SSRIs and suicide attempts.

They found that patients taking SSRIs were twice as likely to attempt suicide compared with patients taking placebo. However, no increase in risk was seen when only fatal suicidal attempts were compared between SSRIs and placebo. Finally, they found no difference between patients taking SSRIs and those taking other drugs, known as tricyclic antidepressants.

The authors point out that, while the absolute risk of suicide is low, the widespread use of SSRIs makes this a population health concern. They also warn that major limitations in the published trials may have led to underestimates of the risk of suicide attempts.

The second study reviewed 477 trials submitted by drug companies to the safety review of the Medicines and Healthcare products Regulatory Agency (MHRA). These trials compared SSRIs with placebo in adults with depression and other clinical conditions.

The research team found no evidence that SSRIs increased the risk of suicide. They found weak evidence of an increased risk of self harm, but no evidence of an increased risk of suicidal thoughts.

Increased risks of suicide and self harm caused by SSRIs cannot be ruled out, say the authors, but larger trials with longer monitoring periods are needed to assess the balance of risks and benefits fully. They recommend that patients should be warned of the potential hazard and monitored closely in the early weeks of treatment.

The final study was based on information from the General Practice Research Database and analysed the risk of self harm and suicide in over 146,000 patients taking SSRIs and tricyclic antidepressants for the first time.

Risks of self harm and suicide were no different in patients prescribed SSRIs compared with those prescribe tricyclics. However, under 18s prescribed SSRIs seemed to be at increased risk of self harm.

The finding that SSRIs and tricyclic antidepressants have a similar risk profile with respect to suicide and self harm is reassuring, say the authors. They call for further research to assess the short and long term risks and benefits of antidepressants.

Despite several limitations, these studies provide some useful insights for clinical practice, write experts in an accompanying editorial. For instance, they should make doctors aware that SSRIs and tricyclics may induce or worsen suicidal behaviour during the early phases of treatment and encourage them to monitor patients closely. They should also discourage the routine prescribing of antidepressant drugs in children and adolescents.

"The debate is not yet done, but these papers crystallise arguments that have been drifting in the ether these past months," says Kamran Abbasi, BMJ Acting Editor. "How many people who turned to 'happy pills' would not have done so if they had been fully aware of the potential harms?"

Publication: Papers: BMJ Volume 330, pp 385-93 and 396-99/Editorial: BMJ Volume 330, pp 373-4
On the web: BMJ-British Medical Journal  

Advertise in this space for $10 per month. Contact us today.

Related Suicide News
Understanding gender differences in suicide methods
Countries with high happiness levels also have high suicide rates
More than half college students have suicidal thoughts
Sleep disturbances among the elderly linked to suicide
Genetic variations may predispose some men to suicidal thoughts during treatment for depression
Sleep disorder may cause suicidal tendencies
Suicide rate among NY's ethnic women population alarming
Suicide Risk associated with Pre- and Postnatal and Early Childhood Factors
Antidepressants are of questionable benefit in teenage suicide cases
Cancer survivors at risk for suicidal thoughts

Subscribe to Suicide Newsletter

Enter your email address:

For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

Contact us

RxPG Online



    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)